Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13645MR)

This product GTTS-WQ13645MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13645MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15830MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ497MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ5543MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ13906MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ6507MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ3600MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13838MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW